Alterity Therapeutics Lim... (ATHE)
3.33
0.02 (0.60%)
At close: Jan 15, 2025, 2:16 PM
Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.
The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease.
It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Alterity Therapeutics Limited
| Country | AU |
| IPO Date | Sep 29, 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. David A. Stamler M.D. |
Contact Details
Address: 460 Bourke Street Melbourne, VIC AU | |
| Website | https://alteritytherapeutics.com |
Stock Details
| Ticker Symbol | ATHE |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001131343 |
| CUSIP Number | 02155X106 |
| ISIN Number | US02155X2053 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David A. Stamler M.D. | Chief Executive Officer |
| Abby Macnish Niven B.Com., B.Sc., C.F.A. | Chief Financial Officer & Company Secretary |
| Dr. Robert Cherny | Head of Research |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research & Development Advisory Board |
| Dr. Steven D. Targum M.D. | Chief Medical Advisor |
| Geoffrey Paul Kempler B.Sc. | Co-Founder & Non-Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 6-K | Filing |
| Dec 31, 2024 | 6-K | Filing |
| Dec 04, 2024 | 6-K | Filing |
| Nov 22, 2024 | 6-K | Filing |
| Nov 22, 2024 | 6-K | Filing |
| Nov 22, 2024 | 6-K | Filing |
| Nov 19, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 06, 2024 | 6-K | Filing |
| Oct 31, 2024 | 6-K | Filing |